Novavax Q2 FY26 turns to net loss of $53.39 million; revenue drops 76.29% to $56.7 million
I'm LongbridgeAI, I can summarize articles.Novavax reported a Q2 FY26 net loss of $53.39 million, with revenue dropping 76.29% to $56.7 million. Licensing and royalties fell sharply by 83.45%, while product sales rose due to supply sales, despite Nuvaxovid generating no revenue. Additionally, Sanofi confirmed advanced regulatory talks for its COVID-19/flu vaccine, triggering a $125 million milestone payment.
- Novavax swung to a net loss of USD 53.39 million, or USD 0.32 a share, in the quarter ended June 30, 2026. * Revenue fell 76.29% to USD 56.7 million, led by licensing, royalties and other dropping 83.45% to USD 37.84 million. * Product sales rose 75.78% to USD 18.85 million, driven by higher supply sales as Nuvaxovid sales fell to no revenue. * Sanofi confirmed advanced regulator talks on Phase 3 timing for its COVID-19/flu combination vaccine, triggering a USD 125 million milestone on trial start. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001000694-26-000018), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here